South Indian Journal of Biological Sciences

Open Access Open Access  Restricted Access Subscription Access

Calcium and Phosphorus Metabolisms in Pulmonary Tuberculosis Patient in Tamilnadu


Affiliations
1 Unit of Medical Lab Technology, Department of Advanced Zoology & Biotechnology, Loyola College, Chennai-600 034, India
2 Department of Virology, King Institute of Preventive Medicine & Research, Guindy, Chennai 600 032, Tamilnadu, India
3 Departments of Advanced Zoology & Biotechnology, (LIFE) Loyola College, -600 034, India
4 Departments of Advanced Zoology & Biotechnology, (LIFE) Loyola College, Chennai-600 034, India
5 Units of Immunology, Department of Advanced Zoology & Biotechnology, Guru Nanak College, Chennai-600 042, India
 

The aim of the present study is to determine the prevalence of hypercalcemia, hypocalcemia, hypophosphatemia and hyperphosphatemia in newly diagnosed TB patients before and after six-month duration anti-TB treatment in India. Patients were required to attend the treatment facility daily during the first intensive phase (first 8 weeks) of chemotherapy and then 3 times weekly during the continuation phase. These suspected patient Blood samples were collected from seven groups. Blood samples were collected from the subjects of tuberculosis Hospital at Chennai for before treatment and after treatment variations, fasting blood samples were collected from 8 AM - 9 AM. Experiments were carried out as soon as possible. Serum was analyzed for calcium and phosphorus. Phosphorus TB incidence of the patients before treatment and after the end of six-month treatment was found to be low at levels 1.08 to 1.25 mg/dL, medium levels 2.0 to 4.0 mg/dL and high levels 7.5 to 12.84 mg/dL. Calcium TB incidence of the patients for before treatment and after the end of six-month treatment was found to be low at levels 2.0 to 4.0 mg/dL, medium levels 11.0 to 13.0 mg/dL and high levels 7.5 to 12.84 mg/dL. In the present study, mean serum calcium level is much in newly diagnosed patients as compared to after treatment group which became normal after completion of therapy. However, mean serum phosphorous level was much decreased and increased in newly diagnosed patients as compared to the control which came to normal levels after the anti-tubercular therapy. Our findings propose the probability that early intervention will help achieve calcium and phosphorus conversion and ultimately a successful treatment outcome.

Keywords

Tuberculosis, Calcium, Phosphorus and Multidrug Resistance.
User
Notifications
Font Size

  • Lind L, Ljunghall S. (1990) Hypercalcemia in pulmonary tuberculosis. Upsala Journal Of Medical Sciences, 95(2), 157–160.

  • Chan TY (1997). Differences in vitamin D status and calcium intake: possible explanations for the regional variations in the prevalence of hypercalcemia in tuberculosis. Calcified Tissue International, 60, 91–3.

  • Roussos A, Lagogianni I, Gonis A, Ilias I, Kazi D, Patsopoulos D, Philippou N (2001). Hypercalcaemia in Greek patients with tuberculosis before the initiation of anti-tuberculosis treatment. Respiratory Medicine, 95, 187–190.

  • Soofi A, Malik A, Khan J, Muzaffar S (2004). Severe hypercalcemia in tuberculosis. Journal of Pakistan Medical Association, 54, 213–215.

  • Bailey DG, Bend JR, Arnold JM, Tran LT, Spence JD (1996). Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clinical Pharmacology & Therapeutics, 60(1), 25-33.

  • National Kidney Foundation (2009). KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. http://www.kidney.org /professionals/kdoqi/guidelines_bone/index.htm. Accessed September 16

  • Gutie´ rrez OM, Mannstadt M, Isakova T, et al (2008). Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. The New England Journal of Medicine, 359(6), 584-592.

  • Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998). Association of serum phosphorus and calcium_phosphate product with mortality risk in chronic hemodialysis patients: a national study. American Journal of Kidney Diseases, 31(4), 607-617.

  • Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK (2001). Association of elevated serum PO(4), CaPO (4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. Journal of the American Society of Nephrology, 12(10), 2131-2138.

  • Kalantar-Zadeh K, Kuwae N, Regidor DL, et al (2006). Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney International, 70(4), 771-780.

  • Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P (2005). Mild hyperphosphatemiaand mortality in hemodialysis patients. American Journal of Kidney Diseases, 46 (1), 68-77.

  • Tentori F, Blayney M, Albert J, et al (2008). Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases, 52(3), 519-530.

  • Wald R, Sarnak M, Tighiouart H, et al (2008). Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. American Journal of Kidney Diseases, 52(3), 531-540.

  • 12. Wells HG, Dewitt LM, Long ER (1923). The chemistry of tuberculosis. London: Bailliere Tindall and Cox;

  • Endres DB, Rude RK (2001). Mineral and bone metabolism. In: Burtis CA, Ashwood ER, editors. Tietz Fundamentals of Clinical chemistry. Philadelphia: W.B. Saunders. p. 795

  • Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004). Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology, 15(8), 2208-2218.

  • Abal AT, Jayakrishnan B, Parwer S, El Shamy AS, Khadadah M, Ayed A, Alawi AA (2005): Demographic pattern and clinical characteristics of patients with smear- positive pulmonary tuberculosis in kuwait. Medical Principles and Practice, 14, 306-312.

  • Howe WR, Dellavalle R (2007): Vitamin D deficiency. The New England Journal of Medicine, 357:1981.

  • Bouillon R, Norman AW, Lips P (2007): Vitamin D deficiency. The New England Journal of Medicine, 357,1980-1981

  • Holick MF (2007): Vitamin D deficiency. The New England Journal of Medicine, 357, 266-281.

  • Payne HA, Menson E, Sharland M, Bryant PA (2011). Symptomatic hypercalcaemia in paediatric tuberculosis. European Respiratory Review, 20(119), 53–56.

  • Lavender TW, Martineau AR, Quinton R, Schwab U (2012). Severe hypercalcaemia following vitamin D replacement for tuberculosis-associated hypovitaminosis D. International Journal of Tuberculosis and Lung Disease, 16 (1), 140.

  • So E1, Bolger DT Jr (2014): Hypercalcaemia: atypical presentation of miliary tuberculosis. BMJ Case Reports, 25, 2014.


Abstract Views: 212

PDF Views: 9




  • Calcium and Phosphorus Metabolisms in Pulmonary Tuberculosis Patient in Tamilnadu

Abstract Views: 212  |  PDF Views: 9

Authors

Subramani Sundaresan
Unit of Medical Lab Technology, Department of Advanced Zoology & Biotechnology, Loyola College, Chennai-600 034, India
Savariar Vincent
Unit of Medical Lab Technology, Department of Advanced Zoology & Biotechnology, Loyola College, Chennai-600 034, India
Srinivasan Sivasubramanian
Department of Virology, King Institute of Preventive Medicine & Research, Guindy, Chennai 600 032, Tamilnadu, India
Pavattan Nallamuthu
Departments of Advanced Zoology & Biotechnology, (LIFE) Loyola College, -600 034, India
Karuthakannan Kannan
Departments of Advanced Zoology & Biotechnology, (LIFE) Loyola College, Chennai-600 034, India
S. S. Jayaraj
Units of Immunology, Department of Advanced Zoology & Biotechnology, Guru Nanak College, Chennai-600 042, India

Abstract


The aim of the present study is to determine the prevalence of hypercalcemia, hypocalcemia, hypophosphatemia and hyperphosphatemia in newly diagnosed TB patients before and after six-month duration anti-TB treatment in India. Patients were required to attend the treatment facility daily during the first intensive phase (first 8 weeks) of chemotherapy and then 3 times weekly during the continuation phase. These suspected patient Blood samples were collected from seven groups. Blood samples were collected from the subjects of tuberculosis Hospital at Chennai for before treatment and after treatment variations, fasting blood samples were collected from 8 AM - 9 AM. Experiments were carried out as soon as possible. Serum was analyzed for calcium and phosphorus. Phosphorus TB incidence of the patients before treatment and after the end of six-month treatment was found to be low at levels 1.08 to 1.25 mg/dL, medium levels 2.0 to 4.0 mg/dL and high levels 7.5 to 12.84 mg/dL. Calcium TB incidence of the patients for before treatment and after the end of six-month treatment was found to be low at levels 2.0 to 4.0 mg/dL, medium levels 11.0 to 13.0 mg/dL and high levels 7.5 to 12.84 mg/dL. In the present study, mean serum calcium level is much in newly diagnosed patients as compared to after treatment group which became normal after completion of therapy. However, mean serum phosphorous level was much decreased and increased in newly diagnosed patients as compared to the control which came to normal levels after the anti-tubercular therapy. Our findings propose the probability that early intervention will help achieve calcium and phosphorus conversion and ultimately a successful treatment outcome.

Keywords


Tuberculosis, Calcium, Phosphorus and Multidrug Resistance.

References